


Name	Kyung-Wook Jo	
Country	Republic of Korea	
Organization	Asan Medical Center	
Current Position	Associate professor	

Educational Background

- 1997.3 – 2003.2 College of Medicine, Chunnam National University
Gwangju, Korea
(Doctor of Medicine)
- 2006.3 – 2008.2 Graduate School, Ulsan University
Ulsan, Korea
(MSc in Medicine)
- 2013.3 – 2017.2 Graduate School, Ulsan University
Ulsan, Korea
(Ph.D. in Medial science)

Professional Experiences

- 2003.3 - 2004.2 Internship in Asan Medical Center, Seoul, Korea
- 2004.3 - 2008.2 Residency in Internal Medicine
Asan Medical Center, Seoul, Korea
- 2012.3 - Fellowship in Division of Pulmonology & Critical Care Medicine,
Asan Medical Center, Seoul, Korea

Professional Organizations

- 2014.3- Assistant professor in Division of Pulmonology & Critical Care
Medicine, Asan Medical Center, Seoul, Korea
- 2019.3- Associate professor in Division of Pulmonology & Critical Care
Medicine, Asan Medical Center, Seoul, Korea

Main Scientific Publications

1. Jo KW, Woo JH, Hong Y, Choi CM, Oh YM, Lee SD, Kim WS, Kim DS, Kim WD, Shim TS. Incidence of tuberculosis among health care workers at a private university hospital in South Korea. *Int J Tuberc Lung Dis.* 2008;12:436-40.
2. Jo KW, Ra SW, Chae EJ, Seo JB, Kim NK, Lee JH, Kim EK, Lee YK, Kim TH, Huh JW, Kim WJ, Lee JH, Lee SM, Lim SY, Shin TR, Yoon HI, Sheen SS, Lee JS, Lee SD, Oh YM. Three phenotypes of obstructive lung disease in the elderly. *Int J Tuberc Lung Dis.* 2010;14:1481-8.
3. Jo KW, Jeon K, Kang YA, Koh WJ, Kim KC, Kim YH, Yoo KH, Lee SH, Yim JJ, Choi SB, Choi WI, Choi JC, Hwang YI, Shim TS. Poor correlation between tuberculin skin tests and interferon-g assays in close contacts of patients with multidrug-resistant tuberculosis. *Respirology* 2012;17:1125-1130

4. Jo KW, Ji W, Hong Y, Lee SD, Kim WS, Kim DS, Shim TS. The efficacy of rifabutin for rifabutin-susceptible, multidrug-resistant tuberculosis. *Respir Med* 2013;107:292-297
5. Jo KW, Hong Y, Park JS, Bae IG, Eom JS, Lee SR, Cho OH, Choo EJ, Heo JY, Woo JH, Shim TS. Prevalence of Latent Tuberculosis Infection among Health Care Workers in South Korea: A Multicenter Study. *Tuberc Respir Dis* 2013;75:18-24 (in Korean)
6. Jo KW, Hong Y, Jung YJ, Yoo B, Lee CK, Kim YG, Yang SK, Byeon JS, Kim KJ, Ye BD, Lee SD, Kim WS, Kim DS, Shim TS. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis. *Respir Med*. 2013 Nov;107(11):1797-802
7. Jo KW, Lee SD, Kim WS, Kim DS, Shim TS. Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis*. 2014;18:39-43
8. Jo KW, Yoo JW, Hong Y, Lee JS, Lee SD, Kim WS, Kim DS, Shim TS. Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen. *Respir Med*. 2014;108:654-659.
9. Jo KW, Kim S, Lee JY, Lee SD, Kim WS, Kim DS, Shim TS. Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy. *J Infect Chemother*. 2014;20:602-606.
10. Jo KW, Kim HR, Kim DK, Kim YH, Park SI, Choi SH, Choi CM. Value of Flexible Bronchoscopy for the Preoperative Assessment of NSCLC Diagnosed Using Percutaneous Core Needle Biopsy. *Thorac Cardiovasc Surg*. 2014;62:593-598.
11. Lee JY, Chon GR, Park JH, Kang BJ, Shim TS, Jo KW. Massive hemoptysis due to pulmonary vein stenosis following catheter ablation for atrial fibrillation. *Respir Care*. 2015;60:e52-55.
12. Lee JY, Chon GR, Jung TY, Sung H, Shim TS, Jo KW. A Case of *Segniliparus rugosus* Pulmonary Infection in an Immunocompetent Patient with Non-cystic Fibrosis. *Tuberc Respir Dis*. 2015;77:227-9.
13. Lee BY, Kim S, Hong Y, Lee SD, Kim WS, Kim DS, Shim TS, Jo KW. Risk factors for recurrence after successful treatment for *Mycobacterium avium* complex lung disease. *Antimicrob Agents Chemother*. 2015;59:2972-2977
14. Jo KW, Yoon S, Song JW, Shim TS, Lee SW, Lee JS, Kim DY, Lee JH, Lee JH, Choi Y, Lee KH. The efficacy of prophylactic azithromycin on bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. *Int J Hematol*. 2015;102:357-363
15. Jeon MK, Yoon JA, Kim J, Yi S, Sung H, Shim TS, Jo KW. Lung Disease Caused by *Mycobacterium mageritense* in an Immunocompetent Patient. *Tuberc Respir Dis*. 2015;78:293-296
16. Yang JY, Oh SY, Song JW, Shim TS, Lee SW, Lee JS, Kim DY, Lee JH, Lee JH, Lee KH, Jo KW. Restrictive chronic lung function decline after haematopoietic stem cell transplantation. *Eur Respir J*. 2016;47:336-339

-
17. Yang JY, Han M, Koh Y, Kim WS, Song JW, Oh YM, Lee SD, Lee SW, Lee JS, Lim CM, Choi CM, Huh JW, Hong SB, Shim TS, Jo KW. Effects of Corticosteroids on Critically Ill Pulmonary Tuberculosis Patients With Acute Respiratory Failure: A Propensity Analysis of Mortality. *Clin Infect Dis.* 2016 ;63:1449-1455.
 18. Jo KW, Yeo Y, Sung H, Kim MN, Shim TS. Analysis of discrepant results between the Genotype® MTBDRplus assay and an antimicrobial drug susceptibility test for isoniazid-resistant tuberculosis. *Respir Med.* 2017;122:12-17
 19. Huh JY, Lee D, Ahn J, Shim JH, Lim YS, Park GC, Song GW, Kim KH, Jung DH, Moon DB, Hwang S, Lee SG, Lee SW, Song JW, Oh YM, Shim TS, Jo KW. Impact of emergency adult living donor liver transplantation on the survival of patients with antituberculosis therapy-induced acute liver failure. *Liver Transpl.* 2017;23:845-846.
 20. Jo KW. Preventing the Transmission of Tuberculosis in Health Care Settings: Administrative Control. *Tuberc Respir Dis.* 2017;80:21-26
 21. Jo KW, Lee S, Kang MR, Sung H, Kim MN, Shim TS. Frequency and Type of Disputed rpoB Mutations in Mycobacterium tuberculosis Isolates from South Korea. *Tuberc Respir Dis.* 2017;80:270-276
 22. Park S, Jo KW, Lee SD, Kim WS, Shim TS. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. *Respir Med.* 2017;131:43-48.
 23. Jeong DH, Kang J, Jung YJ, Yoo B, Lee CK, Kim YG, Hong S, Shim TS, Jo KW. Comparison of latent tuberculosis infection screening strategies before tumor necrosis factor inhibitor treatment in inflammatory arthritis: IGRA-alone versus combination of TST and IGRA. *PLoS One.* 2018 Jul 5;13(7):e0198756
 24. Kwon BS, Kim MN, Sung H, Koh Y, Kim WS, Song JW, Oh YM, Lee SD, Lee SW, Lee JS, Lim CM, Choi CM, Huh JW, Hong SB, Park S, Shim TS, Chong YP, Jo KW. In vitro minimal inhibitory concentrations of rifampin and ethambutol, and treatment outcome in Mycobacterium avium complex lung disease. *Antimicrob Agents Chemother.* 2018 Jul 5;13(7):e0198756
 25. Kim OH, Kwon BS, Han M, Koh Y, Kim WS, Song JW, Oh YM, Lee SD, Lee SW, Lee JS, Lim CM, Choi CM, Huh JW, Hong SB, Shim TS, Jo KW. Association between duration of aminoglycoside treatment and outcome of cavitary Mycobacterium avium complex lung disease. *Clin Infect Dis.* 2019 May 17;68(11):1870-1876.
 26. Kang J, Jeong DH, Yoo B, Lee CK, Kim YG, Hong S, Shim TS, Jo KW. The usefulness of routine chest radiograph examinations in patients treated with TNF inhibitors for inflammatory arthritis in South Korea. *Respir Med.* 2018 Oct;143:109-115.
 27. Kwon BS, Shim TS, Jo KW. The second recurrence of MAC lung disease after successful treatment for first recurrence. *Eur Respir J.* 2019 Jan 3;53(1):1801038
-

-
28. Kang J, Jeong DH, Han M, Yang SK, Byeon JS, Ye BD, Park SH, Hwang SW, Shim TS, Jo KW. Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease. *J Korean Med Sci.* 2018 Oct 23;33(47):e292
29. Kang J, Kim YJ, Shim TS, Jo KW. Risk for cardiovascular disease in patients with nontuberculous mycobacteria treated with macrolide. *J Thorac Dis.* 2018 Oct;10(10):5784-5795.
30. Kwon BS, Lee JH, Koh Y, Kim WS, Song JW, Oh YM, Lee SD, Lee SW, Lee JS, Lim CM, Choi CM, Huh JW, Hong SB, Shim TS, Jo KW. The natural history of non-cavitary nodular bronchiectatic *Mycobacterium avium* complex lung disease. *Respir Med.* 2019 Apr;150:45-50.
31. Jo KW, Kim M, Kim YJ, Lee HK, Kim HK, Jeon D, Lyu J, Park HK, Mok J, Kim JS, Heo EY, Choi SB, Yim JJ, Shim TS. Early discontinuation of ethambutol in pulmonary tuberculosis treatment based on results of the GenoType MTBDRplus assay: A prospective, multicenter, non-inferiority randomized trial in South Korea. *Antimicrob Agents Chemother.* 2019 Sep 16;63(12):e00980-19.
32. Jo KW, Kim JS, Kwon HS, Park YE, Kim JY, Hong MJ, Shim TS. Adverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workers. *Respir Med.* 2019 Oct - Nov;158:42-48.
33. Kwon YS, Han M, Kwon BS, Kim OH, Lee HY, Shim TS, Chong YP, Jo KW. Discontinuation rates attributed to adverse events and treatment outcomes between clarithromycin and azithromycin in *Mycobacterium avium* complex lung disease: A propensity score analysis. *J Glob Antimicrob Resist.* 2020 Jan 28;22:106-112.
34. Jo KW, Park YE, Chong YP, Shim TS. Spontaneous sputum conversion and reversion in *Mycobacterium abscessus* complex lung disease. *PLoS One.* 2020 Apr 27;15(4):e0232161
35. Park YE, Chong YP, Kim YJ, Kim OH, Kwon BS, Shim TS, Jo KW. Outcome of shorter treatment duration in non-cavitary nodular bronchiectatic *Mycobacterium avium* complex lung disease. *J Thorac Dis.* 2020 Mar;12(3):338-348.
36. Kwon YS, Kwon BS, Kim OH, Park YE, Shim TS, Chong YP, Jo KW. Treatment Outcomes after Discontinuation of Ethambutol due to Adverse Events in *Mycobacterium avium* Complex Lung Disease. *J Korean Med Sci.* 2020 Mar 9;35(9):e59.
37. Lee JH, Kim OH, Kim YJ, Shim TS, Jo KW. Changes in chest X-ray findings in 1- and 2-month group after treatment initiation for suspected pulmonary tuberculosis. *Korean J Intern Med.* 2020 Feb 18. doi: 10.3904/kjim.2019.036.
38. Park YE, Kim HJ, Jhun BW, Park Y, Park J, Kwak N, Yim JJ, Shim TS, Kang YA, Jo KW. Prediction of 1-year treatment outcome using early sputum culture conversion status in *Mycobacterium abscessus* pulmonary disease. *J Glob Antimicrob Resist.* 2021 Jun;25:117-118.
-

-
39. Kim OH, Chong YP, Shim TS, Jo KW. Redevelopment after spontaneous sputum conversion in noncavitary nodular bronchiectatic Mycobacterium avium complex lung disease. *J Infect Chemother.* 2021 Aug;27(8):1156-1161.
40. Han DW, Jo KW, Kim OH, Shim TS. Cavity formation and its predictors in noncavitary nodular bronchiectatic Mycobacterium avium complex pulmonary disease. *Respir Med.* 2021 Apr;179:106340.
41. Lee JY, Oh K, Hong HS, Kim K, Hong SW, Park JH, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Lee HS, Jo KW, Park SH. Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea. *BMC Gastroenterol.* 2021 Oct 20;21(1):390.
42. Chae G, Park YE, Chong YP, Lee HJ, Shim TS, Jo KW. Treatment Outcomes of Cavitary Nodular Bronchiectatic-Type Mycobacterium avium Complex Pulmonary Disease. *Antimicrob Agents Chemother.* 2022 Sep 20;66(9):e0226121.
43. Park YE, Chong YP, Lee HJ, Shim TS, Jo KW. Clinical Outcome with Standard Regimen plus Clofazimine or Moxifloxacin in Cavitary Mycobacterium avium Complex Pulmonary Disease. *Antimicrob Agents Chemother.* 2022 Dec 20;66(12):e0052822.
44. Choi MG, Ye BD, Yang SK, Shim TS, Jo KW, Park SH. The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea. *J Korean Med Sci.* 2022 Apr 11;37(14):e107.
45. Kim MA, Park YE, Chong YP, Shim TS, Jo KW. Neutrophil-Lymphocyte Ratio and Monocyte-Lymphocyte Ratio According to the Radiologic Severity of Mycobacterium avium Complex Pulmonary Disease. *J Korean Med Sci.* 2022 Oct 17;37(40):e292.
46. Park YE, Lee JH, Chong YP, Lee HJ, Kim HC, Song JW, Shim TS, Jo KW. Treatment outcomes of the interstitial lung disease subtype of unclassifiable type Mycobacterium avium complex pulmonary disease. *J Infect Chemother.* 2022 Aug;28(8):1112-1118.
47. Lee JH, Park YE, Chong YP, Shim TS, Jo KW. Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types. *Antimicrob Agents Chemother.* 2022 Feb 15;66(2):e0152221.
48. Park YE, Park SY, Jhun BW, Park Y, Kang YA, Park J, Kwak N, Yim JJ, Shim TS, Jo KW. Treatment outcome of continuation of intravenous amikacin for Mycobacterium abscessus pulmonary disease with a persistent culture positivity after the treatment initiation. *J Infect Chemother.* 2022 Aug;28(8):1098-1104.
49. Kim OH, Shim TS, Jo KW. Drug-level change and optimal dose adjustment of tacrolimus with the use of rifabutin for treating mycobacterial disease in solid organ transplant recipients. *Transpl Infect Dis.* 2022 Aug;24(4):e13893.
-

50. Lee JH, Park YE, Chong YP, Lee HJ, Shim TS, Jo KW. Radiologic Subtypes and Treatment Outcome of Unclassifiable Type Mycobacterium avium Complex Pulmonary Disease. *J Korean Med Sci.* 2023 Jan 16;38(3):e16.
52. Kim HH, Kim S, Kim MA, Jung CH, Chong YP, Shim TS, Kim YJ, Jo KW. Stratification of Nontuberculous Mycobacterial Disease Risk in Type 2 Diabetes Based on Metformin Use: a Population-Based Cohort Study in South Korea. *Antimicrob Agents Chemother.* 2023 Jun 15;67(6):e0167522
53. Kim SM, Chong YP, Lee HJ, Shim TS, Jo KW. Comparison of Treatment Outcomes of Cavitory Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use. *Microbiol Spectr.* 2023 Jun 15;11(3):e0474122
54. Jeon DS, Kim S, Kim MA, Chong YP, Shim TS, Jung CH, Kim YJ, Jo KW. Type 2 Diabetes Mellitus- and Complication-Related Risk of Nontuberculous Mycobacterial Disease in a South Korean Cohort. *Microbiol Spectr.* 2023 Mar 28;11(2):e0451122.
-